secwatch.observer — SEC 8-K summary
======================================

Issuer:     Surrozen, Inc./DE (SRZN)
CIK:        0001824893
Form:       8-K
Filed at:   2022-01-10T23:59:59+00:00
Accession:  0000950170-22-000190
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Surrozen expects to start Phase 1 trials for SZN-1326 and SZN-043 in Q3 2022; nominates SZN-413 candidate
--------------------------------------------------------------------------------

- Expects to initiate Phase 1 clinical trials of SZN-1326 and SZN-043 in Q3 2022.
- Nominated SZN-413, a mono Fzd4 bi-specific antibody, for retinal vascular diseases including wet AMD and diabetic retinopathies.
- None of the product candidates have been tested in humans or gained regulatory approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824893/000095017022000190/0000950170-22-000190-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824893/000095017022000190/srzn-20220110.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-000190

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer